Systemic Inflammation Response Index (SIRI) as a Novel Predictor for All-Cause Mortality in Patients with Inflammatory Bowel Disease

Technical Summary: Systemic Inflammation Response Index (SIRI) as a Predictor for All-Cause Mortality in IBD Patients

Problem Statement
Inflammatory Bowel Disease (IBD), comprising Crohn's disease and ulcerative colitis, imposes a growing global health burden characterized by systemic inflammation that contributes to excess mortality via cardiovascular events, malignancies, and thromboembolic complications. While the Systemic Inflammation Response Index (SIRI)—a composite biomarker derived from neutrophil, monocyte, and lymphocyte counts—has shown prognostic value in various malignancies and critical diseases, its specific predictive capability for all-cause mortality in IBD patients remains largely unexplored. This study addresses the gap in literature regarding whether SIRI can serve as a robust, novel biomarker for mortality risk stratification in the IBD population.

Methodology
The study utilized data from the UK Biobank, a large-scale prospective cohort.

• Cohort Selection: From an initial pool of 7,948 participants with IBD identified via self-report, primary care records, and hospitalization datasets (ICD-10 codes K50 and K51), the final analytical cohort consisted of 7,060 individuals. Exclusion criteria included missing baseline SIRI or demographic data and death within the first year of recruitment.
• Exposure Assessment: SIRI was calculated at baseline using the formula: Neutrophil count × Monocyte count / Lymphocyte count.
• Outcome Assessment: The primary outcome was all-cause mortality, tracked via linkage to national death registries (NHS Information Centre and NHS Central Register for Scotland) with censoring dates set in late 2021.
• Statistical Analysis:
  • Cox Proportional Hazards Models: Three hierarchical models were employed to calculate Hazard Ratios (HRs) and 95% Confidence Intervals (CIs). Model 1 was unadjusted; Model 2 adjusted for age and sex; Model 3 included comprehensive adjustments for ethnicity, BMI, Townsend deprivation index (TDI), education, physical activity, smoking status, and medication use.
  • Non-linearity: Restricted Cubic Spline (RCS) regression was used to explore dose-response relationships and identify potential thresholds.
  • Mediation Analysis: Causal mediation analysis was conducted to evaluate the roles of Handgrip strength, Red Blood Cell Distribution Width (RDW), and C-reactive protein (CRP) as mediators in the SIRI-mortality pathway.
  • Subgroup Analysis: Stratified analyses were performed across demographics and clinical characteristics to assess consistency.

Key Results

• Independent Association: After full adjustment (Model 3), elevated SIRI was independently associated with increased all-cause mortality. Each unit increase in SIRI corresponded to a 5.4% increase in mortality hazard (HR = 1.054, 95% CI: 1.037–1.071).
• Quartile Comparison: Participants in the highest SIRI quartile (Q4) faced a 1.9-fold higher mortality hazard compared to those in the lowest quartile (Q1) (HR = 1.910, 95% CI: 1.604–2.275).
• Non-linear Relationship: RCS analysis revealed a significant non-linear association (P < 0.001). A threshold effect was identified at a SIRI value of 1.24; below this value, mortality risk remained relatively low, while risk increased sharply as SIRI exceeded 1.24.
• Mediation Pathways: The study identified partial mediation effects:
  • Handgrip Strength: Negatively correlated with SIRI; lower strength mediated increased mortality risk.
  • RDW: Positively predicted by SIRI and significantly correlated with mortality odds, acting as a mediator.
  • CRP: SIRI upregulated CRP levels, which in turn influenced mortality risk.
• Subgroup Consistency: The positive association between SIRI and mortality was observed across all subgroups (gender, age, ethnicity, BMI, etc.), though significant interactions were noted for gender, age, education, TDI, and medication use.

Significance and Claims
The authors claim that this study provides the first evidence linking elevated SIRI to all-cause mortality in IBD patients using a large, prospective cohort. The primary significance lies in identifying SIRI as a practical, cost-effective biomarker derived from routine blood tests that can help identify high-risk IBD patients.

The study posits that the relationship is non-linear, with a specific risk threshold (1.24) that could inform clinical decision-making. Furthermore, the mediation analysis suggests that the mechanism linking SIRI to mortality involves systemic inflammation, erythrocyte homeostasis dysregulation (via RDW), and physical frailty (via handgrip strength). The authors conclude that SIRI may serve as a valuable tool for risk stratification and guiding clinical management, potentially improving long-term prognosis by enabling earlier identification of patients at risk of fatal complications.

Limitations Acknowledged
The authors note that SIRI was measured only at baseline, precluding the evaluation of time-dependent changes. They also acknowledge potential residual confounding from unmeasured variables such as specific disease activity, treatment compliance, and diet. Additionally, the sample's demographic homogeneity (predominantly White adults) limits the generalizability of findings to children or diverse ethnic populations.